Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3 studies found for:    DNIB0600A
Show Display Options
Rank Status Study
1 Completed A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
Condition: Ovarian Cancer
Interventions: Drug: DNIB0600A;   Drug: PLD
2 Active, not recruiting A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Bevacizumab;   Drug: Carboplatin;   Drug: DNIB0600A
3 Completed Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
Condition: Non-Squamous Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A

Study has passed its completion date and status has not been verified in more than two years.